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Abstract
Myeloid cells play numerous roles in HIV-1 pathogenesis serving as a vehicle for viral spread and as a viral reservoir. Yet, cells
of this lineage generally resist HIV-1 infection when compared to cells of other lineages, a phenomenon particularly acute
during the early phases of infection. Here, we explore the role of APOBEC3A on these steps. APOBEC3A is a member of the
APOBEC3 family that is highly expressed in myeloid cells, but so far lacks a known antiviral effect against retroviruses. Using
ectopic expression of APOBEC3A in established cell lines and specific silencing in primary macrophages and dendritic cells,
we demonstrate that the pool of APOBEC3A in target cells inhibits the early phases of HIV-1 infection and the spread of
replication-competent R5-tropic HIV-1, specifically in cells of myeloid origins. In these cells, APOBEC3A affects the amount of
vDNA synthesized over the course of infection. The susceptibility to the antiviral effect of APOBEC3A is conserved among
primate lentiviruses, although the viral protein Vpx coded by members of the SIVSM/HIV-2 lineage provides partial
protection from APOBEC3A during infection. Our results indicate that APOBEC3A is a previously unrecognized antiviral
factor that targets primate lentiviruses specifically in myeloid cells and that acts during the early phases of infection directly
in target cells. The findings presented here open up new venues on the role of APOBEC3A during HIV infection and
pathogenesis, on the role of the cellular context in the regulation of the antiviral activities of members of the APOBEC3
family and more generally on the natural functions of APOBEC3A.
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Introduction
The apolipoprotein B mRNA editing enzyme, catalytic
polypeptide-like 3 family (APOBEC3s) comprises 6 members of
highly related cytidine deaminases [1]. The prototype of the
family, APOBEC3G (or A3G), has been identified on the basis of
its ability to inhibit HIV-1 infection in the absence of the Vif
protein [2]. In this case, the antiviral effect of A3G is exerted via its
incorporation into virion particles in virus-producing cells. This
incorporation leads to the deamination of newly synthesized viral
DNA during the subsequent cycle of infection [3–6], although a
non-deaminase dependent mechanism of inhibition has also been
described [7,8]. In the presence of Vif, A3G is targeted to an E3-
ubiquiting ligase complex and is thus degraded in virus-producing
cells [9–17]. Even if this seems the major mechanism with which
the virus protects itself, retroviruses can use a Vif-independent
manner that does not involve the degradation of A3G, but results
in the exclusion of the protein from assembling viral particles [18–
21]. In the case of HIV-1, Vif has also been proposed to promote
structural changes in A3G that negatively affect its ability to be
incorporated into virion particles [22,23].
While this host-pathogen struggle takes place in producing cells,
the role of the pool of A3G molecules present in target cells and
thus welcoming incoming viral particles remains unclear and in
large part unexplored [24,25]. The possibility that APOBEC3
members might exert an inhibitory effect directly on incoming
viruses is interesting, because in these steps Vif is absent (or present
only in trace amounts in virion particles), so that the virus would
be denuded of protection against them [26,27]. A3G has been
reported to block the early phases of HIV-1 infection of quiescent
T cells and DCs, but this activity has been recently ascribed to
more general modifications of the activation status of quiescent
lymphocytes, rather than to a specific effect of A3G silencing
during the early phases of infection [24,25].
All the members of the APOBEC3 family coded by primates (A
through H) exhibit antiviral properties, although their potency
may vary (for review see [28,29] and [30] for the specific case of
A3H). The exception to this rule is APOBEC3A (A3A) that is to
date the only member of the APOBEC3 family whose ectopic
expression in established cell lines (HeLa or HEK293T cells) bears
no consequence for retroviruses [21,31]. APOBEC3A is a single-
domain cytidine deaminase, it is capable of editing exogenous and
endogenous DNA upon expression in HeLa cells and has been
shown to be responsible for the strong editing activity observed in
primary monocytes [32–35]. A3A is capable of inhibiting the
replication of LTR and non-LTR retroelements [36–39], of
Parvoviruses [36] and has more recently been shown to
moderately inhibit Alpharetroviruses (more specifically the Rous
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[40]). Increased expression of A3A, along with other APOBEC3
members, has been observed in keratinocytes and skin of
precancerous cervical biopsies of human papillomavirus (HPV)-
positive patients, presence that has been correlated to an increased
evidence of HPV editing [41]. Although certain studies suggest
that the editing activity of A3A may play a role in the host cell
genome integrity and advance the hypothesis that this activity may
lead or contribute to cancerogenesis [34], the inhibition of
retroelements and of the adeno-associated virus 2 (AAV2) seems
independent from the deaminase activity of A3A [36–39].
In the case of HIV-1, no firm evidence links A3A to an antiviral
activity in either producing or receiving cells, although one study
advanced the hypothesis that the increased replication of HIV-1 in
differentiated macrophages over monocytes could be due to their
lower content in A3A [42]. Together with a few recent articles
indicating that A3A could be preferentially expressed in cells of the
myeloid lineage, these reports call for a deeper analysis of the
relationship existing between HIV-1 and myeloid cells [43,44].
Primary circulating blood monocytes, along with differentiated
macrophages and dendritic cells (DCs) are key cells in immune
responses acting both as sentinels of danger signals, as well as
instructors for other cells of the immune system (reviewed recently
in [45–47]. These cells represent an important target for HIV-1
replication and have been shown to serve both as a vehicle for its
dissemination through the body, as well as a viral reservoir.
However, myeloid cells are collectively more resistant to HIV-1
infection than other cell types, as for example activated
lymphocytes. This resistance varies according to the differentiation
status and stimulation present and appears at different steps of the
viral life cycle. Among these steps, a major impairment occurs
during the early phases of infection, as a number of laboratories
including ours have established [48–55]. The exact nature of this
resistance is unclear and likely to be multifactorial. However, a
number of recent evidences point to the existence of cellular
restriction factors that affect incoming virus specifically in the
peculiar environment of myeloid cells [50,56]. In this respect, two
very recent studies identified one such factor in SAMHD1, whose
alternative name is dendritic cells derived interferon c-induced
protein (DCIP) [57] and the deficiency of which causes the
Aicardi-Goutie `res syndrome, a disease in which interferon
responses are deregulated [58]. Despite the fact that SAMHD1
is expressed in different cell types, it seems to restrict lentiviral
infection specifically in myeloid cells, probably highlighting the
need for a particular cellular context, or for specific cellular
partners [59,60].
Given that previous reports indicated that A3A was preferen-
tially expressed in CD14-positive monocytes [42–44], we tried to
determine whether the pool of A3A molecules present in target
cells could inhibit de novo infection of myeloid cells by HIV-1.
To this end, we first determined that A3A is the sole member of
the APOBEC3 family specifically expressed in different myeloid
cells. Then, using either ectopic expression of A3A in established
HeLa cells or specific silencing in primary macrophages and DCs,
we determined that A3A does indeed inhibit the early phases of
infection specifically in myeloid cells. Indeed, silencing of A3A not
only increases the susceptibility of target cells to HIV-1 during
single round infectivity assays, but also augments the spread of R5
tropic HIV-1 viruses. This antiviral effect is mediated by the pool
of A3A present in target cells and is exerted through a decrease in
viral DNA accumulation. The identification of TC editing in
vDNA produced during HIV-1 infection of myeloid cells suggests
that this antiviral mechanism may at least in part be exerted via
deamination of the viral genome. The inhibition mediated by A3A
targets also SIVMAC viruses, suggesting a conserved antiviral
mechanism directed against primate lentiviruses. Finally, we
provide evidence that Vpx, a protein coded by members of the
SIVSM/HIV-2 lineage seems to provide partial protection against
A3A by driving its degradation.
Results
A3A is the only member of the APOBEC3 family
specifically expressed in primary blood cells of myeloid
origins
A few reports have indicated that among circulating white blood
cells, A3A was highly expressed in monocytes [42–44]. To
determine more widely the pattern of expression of A3A and of
the different members of the APOBEC3 family, quantitative RT-
PCR was performed on quiescent or PHA-stimulated primary
blood cells (PBLs, depleted of monocytes), monocytes, macro-
phages and dendritic cells (DCs) differentiated upon incubation of
monocytes for 4 to 5 days with M-CSF and GM-CSF/IL4,
respectively (Figure 1). Our analysis reveals that A3A is
overexpressed by at least 100 fold in differentiated macrophages
over PBLs, irrespectively of their activation status. This difference
increases further in DCs and is the greatest in monocytes in which
A3A is expressed over 5 logs more than in stimulated PBLs. The
expression of the remaining APOBEC3 members did not display
such cell type specific variations, with the exception of A3D/E that
seems expressed at least 10 fold more in PBLs than in the myeloid
cells tested. On the contrary, A3B and to a lower extent A3H are
less expressed in non-stimulated monocytes than in stimulated
PBLs, although their expression increased during differentiation
into either macrophages or DCs. Overall, myeloid cells express
consistent levels of all APOBEC3 members, but A3A is the only
one whose expression is restricted to them. These results are in line
with previous reports and extend them in the absolute quantifi-
cation of the copy number of the different APOBEC3 members
during the differentiation of circulating monocytes into macro-
phages and DCs. Of note, IFNa treatment increased the
expression levels of A3A at both the mRNA and protein level,
Author Summary
Macrophages and dendritic cells represent important
targets for HIV-1 and the understanding of the complex
relationship established between these cells and the virus
is of the outmost importance. Here, we show that
APOBEC3A, the least known member of the APOBEC3
family of cytidine deaminases, restricts HIV-1 specifically in
these cells. The antiviral effect of APOBEC3A is exerted at
viral DNA accumulation during de novo infection through a
mechanism that may involve deamination. For the first
time, our results indicate that APOBEC3A, rather than
being devoid of inhibitory activity against HIV-1, plays an
important role in blocking not only HIV-1, but more
generally primate lentiviruses. This antiviral effect is
specific to myeloid cells in which this factor is naturally
expressed. Among the viral proteins capable of opposing
APOBEC3A, we have found that Vpx, a protein coded by
members of the SIVSM/HIV-2 lineage provides a partial
protection against this factor by inducing its degradation.
Overall, these results shed new light on the regulation of
members of the APOBEC3 family in primary cells and open
up new venues on the role that APOBEC3A, a restriction
factor specifically expressed in myeloid cells, may play
during viral pathogenesis.
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untreated cells: monocytes, DCs, macrophages and PBLs (from the
highest to the lowest, Figure S1A and S1B). At the protein level,
we confirm that A3A can be recognized after migration on an
SDS-PAGE gel by the ApoC17 antibody initially raised against
A3G [23] and Figure S2). In our hands, A3A can be detected as a
doublet by WB. Detection of this doublet is however highly
variable and unpredictable, probably influenced by the detection
limit of A3A in a given experiment and by donor-to-donor
variations. In any case, the antiviral effect of A3A seems not linked
to the detection of an A3A doublet by WB.
In conclusion, these results indicate that if myeloid cells express
comparable levels of APOBEC3 members, A3A is the sole
member of the APOBEC3 family whose expression is restricted to
cells of myeloid origins, among cells of hematopoietic origins.
The expression levels of A3A specifically increase during
HIV-1 spread in infected macrophages
To determine whether the levels of A3A were modulated during
the course of HIV-1 infection, M-CSF-differentiated macrophages
were infected with an R5 tropic HIV-1 virus (Yu2) and viral
spread was assessed by determining the amount of virion-
associated RT activity released in the cell supernatant (by exo-
RT, Figure 2A). At day 7, when consistent viral spread had
occurred, cell aliquots were lysed and the levels of APOBEC3
members analyzed at the mRNA level and, for A3A, also at the
protein level by WB (Figures 2B and 2C, respectively). Spreading
HIV-1 infection was associated to a consistent increase in A3A at
both mRNA and protein levels. With the exception of A3B whose
expression decreased during HIV-1 infection, the expression of the
remaining members of the APOBEC3 family was not significantly
modified. This increase was not due to the presence of type I
interferon (IFNs) in the cultures, as assessed by the failure of
supernatant derived from infected macrophages to inhibit the
spread of a GFP-bearing Vesicular Stomatitis Virus in A549 cells
(VSV, Figure S3). This assay is not only extremely sensitive, but
allows the detection of the presence of all the subtypes of IFN a
and b in the culture (in number of 13 and 2, respectively) [61,62].
Although we cannot exclude the secretion of low levels of type I
IFN and subsequent engagement of the IFN receptor, absence of
IFN production during HIV-1 infection of dendritic cells has been
recently reported [63]. Thus, although the expression of A3A can
be induced by type I IFN [35,43,64,65] and Figure S1), its
expression during HIV-1 spreading infection of macrophages can
also increase in a manner that is largely type I IFN-independent.
To further support this argument, the expression of A3G, also
modulated by type I IFN, is not significantly modified during
infection. Thus, the upregulation of A3A observed here is likely to
be part of a more complex response to viral infection that takes
place in infected macrophages.
A3A inhibits the early phases of HIV-1 infection
specifically in myeloid cells
The main described anti-retroviral function of APOBEC3
members involves the pool of APOBEC3s molecules present in
virus-producing cells. On the contrary, the role of the pool of
Figure 1. A3A is preferentially expressed in myeloid cells. Primary blood monocytes, monocyte-derived macrophages and DCs were
compared to PBLs either quiescent or stimulated for 24 hrs with PHA/IL2 to determine the amount of mRNA of the different members of the
APOBEC3 family using primers specific for each member, as already described in [44]. The graph presents results obtained from cells derived from 4
different donors.
doi:10.1371/journal.ppat.1002221.g001
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only for A3G and remains highly debated [24,25]. Among the
members of this family, A3A is to date the sole member devoid of
known inhibitory activity against HIV-1 when overexpressed in
established cell lines [21,31]. In agreement with these previous
results, single cycle infection of HeLa cells overexpressing an HA-
tagged version of A3A (that is editing-competent, data not shown)
did not significantly modulate the susceptibility of target cells to
infection with both complete or minimal HIV-1 vectors (i.e.
containing or lacking non-structural viral proteins, Figure 3A).
Given that no differences were observed between complete and
minimal vectors in the experiments described below, the formers
were routinely used for their slight but consistent higher infectivity
(data not shown and [66]).
Contrarily to what observed in HeLa cells, silencing of A3A
increased the susceptibility of target myeloid cells to HIV-1
infection (Figure 3B). Silencing was established using either miR-
shRNAs expressed upon HIV-1-vectors mediated gene transduc-
tion [67] or liposome-mediated transfection of siRNAs. Silenced
cells were then challenged with GFP-coding HIV-1 vectors. Given
that both silencing methods yielded similar results, the formers
were routinely used, as they allowed for more potent silencing.
Knockdown of A3A increased the susceptibility of all cells of
myeloid origins tested to the challenge with HIV-1 by an average
of 5 to 7 fold: THP-1 differentiated into macrophage-like cells
upon incubation with PMA (Diff. THP-1), as well as macrophages
and DCs (Figure 3B). As expected, knockdown of A3A exerted no
effect on the infection of PHA-stimulated PBLs (in the presence or
absence of IFNa, Figure 3B and Figure S4). This result was
expected as A3A is barely expressed in both quiescent and
activated PBLs even after IFNa treatment, if compared to myeloid
cells. The absence of an effect of the A3A knockdown on the
susceptibility of PBLs to HIV-1 infection suggests the lack of non-
specific effects (i.e. the A3A target must be present for the observed
phenotype). To further control the specificity of our knockdowns,
quantitative RT-PCR analysis was carried out on mRNA
preparations derived from miR-shRNA-silenced macrophages
for all the members of the APOBEC3 family (Figure S5A). This
analysis indicated a specific decrease in A3A mRNA, but not in
the mRNAs of other members of the family. As further proof of
the specificity of the A3A knockdowns, A3A was silenced in
macrophages upon liposome-mediated transfection of siRNAs.
These siRNAs where chosen to target sequences within the A3A
mRNA that were distinct from those targeted by the miR-
shRNAs. Again, knockdown of A3A yielded an increase in the
infectivity of HIV-1 similar to the one observed for miR-shRNAs
(Figure S5B).
Overall, these experiments reveal that A3A plays a specific
antiviral role during the early phases of HIV-1 infection in cells of
myeloid origins in which it is naturally highly expressed.
A3A inhibits spread of HIV-1 in primary macrophages
To determine whether the antiviral effect of A3A could be
observed also during replicative infection, silenced macrophages
were challenged with R5 tropic HIV-1 (Yu2) at MOI of 0,05 and
viral spread monitored by exo-RT activity (Figure 4). Even in this
case, the specific silencing of A3A (shown in the WB side panel)
increased viral spread in the culture. Although this result does not
exclude an effect of A3A in virus-producing cells (the most
classically described antiviral effect of APOBEC3s), this increase
does correlate with the one observed during the early phases of
infection in single round infectivity assays, indicating that A3A
inhibits viral spread in macrophages. In light of the data presented
in Figure 2B indicating an increase of A3A during spreading
infection of HIV-1, we can hypothesize that the effect of silencing
of A3A is mitigated by the overexpression of A3A observed during
spreading HIV-1 infection. Similar experiments were attempted in
DCs, but were abandoned due to the high mortality of silenced
DCs upon viral challenge. This higher mortality is independent
from the identity of the silenced gene, as it is observed in control
and A3A knockdowns alike and does not seem specific for HIV-1.
A3A impairs the accumulation of vDNA during the early
phases of infection, but does not affect the kinetics of
accumulation of infectious vDNA
To identify the step affected by the depletion of A3A in target
cells, silenced macrophages were lysed 24 hours post infection and
the accumulation of vDNA analyzed by qPCR. The use of an
HIV-1 based miR-shRNA vector precluded the analysis of all the
viral DNA products synthesized over the course of infection.
Figure 2. The expression of A3A is specifically increased during HIV-1 spread in infected macrophages. A) M-CSF-derived macrophages
were infected with the R5 tropic HIV-1 strain Yu2 at a multiplicity of infection (MOI) of 0,05. Viral spread over time was measured by determining the
amount of virion-associated RT activity released in the supernatant (exo-RT). Aliquots of macrophages were lysed at day 7 to determine variations in
members of the APOBEC3 family at the mRNA (B) and, in the case of A3A, also at the protein level (C). The panels A and C present one representative
experiment out of three, while the panel B presents the average values obtained with cells derived from 3 different donors.
doi:10.1371/journal.ppat.1002221.g002
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enabled the analysis of vDNA products obtained after the minus
strand strong stop, which represent one of the major restrictive
step during the infection of myeloid cells. Under these conditions,
silencing of A3A increased the accumulation of vDNA by 4 to 5
fold (Figure 5A), in agreement with the increase observed in
infectivity. While the analysis of vDNA products by PCR yields
quantitative data on their accumulation as a whole, this technique
does not reveal the kinetic behavior of truly infectious vDNA.
Infectious vDNA constitutes a minor fraction of the total vDNA
produced during infection [68], a phenomenon that is exacerbated
in primary cells more resistant to infection. Thus, determining the
behavior of these genomes represents an important additional
parameter during the early phases of infection. To determine the
Figure 3. A3A inhibits the early phases of HIV-1 infection specifically in myeloid cells. A) HeLa cells were transfected with either control or
HA-tagged A3A coding constructs and analyzed by WB or challenged 48 hours after transfection with different inputs of VSVg-pseudotyped
complete or minimal HIV-1 vectors (i.e. coding or not viral non-structural proteins), carrying a GFP expression cassette in a single-round infectivity
assay. The percentage of infected cells was determined 3 days later by flow cytometry. The graph presents averages from 4 different experiments. B)
Control or A3A knockdowns were obtained upon LV-mediated transduction of PMA-differentiated THP-1 cells, macrophages, DCs and PHA/IL2-
activated PBLs with an equal viral input of miR-shRNAs coding vectors. Four days later, stably silenced cells were analyzed by WB (right panel,
presenting representative experiments) or challenged with VSVg-pseudotyped GFP-coding HIV-1 vectors (at MOIs comprised between 3 and 5). The
graph presents data obtained from 3 to 6 independent experiments.
doi:10.1371/journal.ppat.1002221.g003
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determine how fast it was completed during infection, we
employed a technique we had previously described [48]. In this
setup, infectious viral genomes are defined as those capable of
expressing the viral-coded GFP reporter and their accumulation
over time is determined by arresting the reverse transcription
process at different times post infection through the addition of the
RT inhibitor Nevirapine. The percentage of GFP-positive cells at
each time point is then determined by flow cytometry 3 days post
infection and values are graphed after normalization to control
infections carried out in the absence of RT inhibitors. This assay
yields a kinetic measurement of the speed at which completion of
infectious vDNA is carried out. In this respect, the assay does not
yield information on the total amount of vDNA synthesized during
infection as in Fig. 5A, but describes another parameter which is
the speed at which infectious vDNA is produced. When control
and A3A-silenced macrophages were thus analyzed, no significant
changes were observed in the kinetics of reverse transcription of
HIV-1 infectious genomes (Figure 5B). These results indicate that
A3A does not modify the kinetics of reverse transcription, but
affects the overall amount of vDNA synthesized. This decrease is
of the same amplitude of the effect observed in viral infectivity.
The intracellular levels of A3A modulate the levels of TC
editing found in vDNA produced during infection of
myeloid cells
Inhibition of AAV or retroelements by A3A seems to follow a
deaminase-independent mechanism. To determine whether this
was the case here, vDNA products accumulated during infection
of macrophages were amplified, cloned and sequenced in search of
potential cytidine editing. HIV-1 vDNA produced in macrophages
exhibited a significantly higher proportion of edited cytidine with
respect to vDNA synthesized in HeLa cells (Figure 5C). This
deamination signature depended at least in part from A3A, since
the number of edited sites decreased upon silencing of A3A. When
the dinucleotide motifs surrounding the edited cytidine were
examined, a minority was found to be CC (described as specific of
A3G), while more than a half were TC (described to be
preferentially recognized by the remaining A3 members)
(Figure 5D). Cytidine deamination of the latter TC motif
depended from A3A as their proportion specifically decreased
upon A3A silencing. Overall, these results indicate that a small yet
detectable cytidine editing signature is present in vDNA produced
during the infection of myeloid cells, a portion of which is clearly
influenced by the intracellular levels of A3A.
The antiviral effect of the A3A pool present in target cells
is conserved among primate lentiviruses. To determine
whether A3A is a specific inhibitor of HIV-1, or if it exerts a
conserved antiviral function directed against primate lentiviruses,
A3A or control-silenced differentiated THP-1 cells and DCs were
challenged with SIVMAC vectors. Given that we have previously
determined that the non-structural protein Vpx plays an important
role during the infection of myeloid cells, Vpx-positive and
deficient SIVMAC viruses were compared side by side (Figure 6A).
Silencing of A3A resulted in an increase in the infectivity of WT
SIVMAC viruses in both differentiated THP-1 cells and DCs,
indicating that A3A targets not only HIV-1, but more generally
primate lentiviruses. A positive effect of A3A silencing was also
observed in the infectivity of SIVMAC vectors devoid of Vpx, that
display a strong defect during the infection of myeloid cells. In
differentiated THP-1, the infectivity of SIVMAC Vpx-deficient
viruses approached –albeit not equaled- that of the WT in control
silenced cells. In DCs, in which SIVMAC Vpx-deficient viruses
display a drastic infectivity defect, silencing of A3A allowed the
detection of infection clearly above the background, although not
to the same levels of WT SIVMAC. These results suggest that the
depletion of A3A may contribute to relieve the defect of Vpx-
minus viruses. This result is of interest for two reasons. First
because we and others have previously determined that Vpx is
required for the completion of the early phases of infection
specifically in myeloid cells in a manner that may involve the
degradation of an unknown cellular restriction factor
Figure 4. A3A silencing increases viral spread of an R5 tropic HIV-1 virus in macrophages. Macrophages stably silenced as above were
infected with an R5 tropic HIV-1 virus (Yu2) at an MOI of 0,05. Viral spread was determined by exo-RT. The graph presents data obtained from 4
independent experiments, while the WB panels present the efficacy of A3A silencing at day 15 in one representative experiment.
doi:10.1371/journal.ppat.1002221.g004
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shown to interact with SIVMAC Vpx upon overexpression in
HeLa cells [72]. Thus, we decided to pursue the characterization
of the relationship between Vpx and A3A further.
SIVMAC Vpx associates functionally to A3A. His-tagged
SIVMAC Vpx and HIV-1 Vpr were purified on nichel columns and
used to pull down endogenous A3A expressed in PMA-treated
THP-1 cells. We have already determined that although these
proteins are structurally related, only SIVMAC Vpx exerts a strong
positive effect during the early phases of infection of myeloid cells
[50]. HIV-1 Vpr was used to filter the lysate obtained from
differentiated THP-1 of non specific interactors, prior to binding
to a second column containing SIVMAC Vpx (Figure 6B). The
different fractions were then subjected to WB analysis for the
indicated proteins (Figure 6C). The DDB1 and CUL4-associated
factor 1 (DCAF1) adaptor was examined, as it has been shown to
associate to both HIV-1 Vpr and Vpx proteins derived from
almost all SIV and HIV-2 strains tested [56,67,69,73–78],
although the relevance of this binding for the functions of Vpx
remains controversial [67,69,70]. As expected, DCAF1 was almost
Figure 5. A3A impacts the accumulation of vDNA, but not the kinetics of reverse transcription of infectious vDNA and modulates
the levels of TC editing of vDNA produced during the infection of myeloid cells. A) Control and A3A-silenced macrophages were
challenged with an equal viral input of GFP-coding HIV-1 virus and cells were lysed at 24 hours post-infection for qPCR analysis with primers specific
for the GFP sequence present uniquely on the challenge virus. The scheme presents the relative position of PCR primers on the HIV-1 genome.
Control infections were carried out in the presence of RT-inhibitors. Given values are normalized for actin and subtracted for those obtained upon
infections carried out in the presence of RT inhibitors (Nevirapine and AZT at 20 mg/ml). B) The kinetics of infectious vDNA accumulation in
macrophages silenced or not for A3A were determined as in [48]. Briefly, the accumulation of infectious genomes, defined as those resulting in a GFP-
positive cell, is determined upon addition of the RT inhibitor Nevirapine at different times post infection. The percentage of vDNA molecules
completed prior to the addition of the inhibitor at each time point is determined 3 days post infection upon normalization to control infections
carried out in the absence of RT inhibitor. This assay yields a measure of the speed at which infectious vDNA accumulates, as described in [48]. The
graph presents a representative experiment out of 3. C) vDNA produced upon infection of HeLa cells or of primary silenced macrophages was
extracted 24 hours post infection, amplified and individual clones, represented by symbols, sequenced. The number of cytidine edited in each
sequence with respect to the reference is shown here. Sequences were obtained from 4 independent experiments. Lines represent averages in each
sample. Asterisks indicate statistically significant differences after a Student t test (* p,0,05;** p,0,01;*** p,0,001). D) Analysis of the dinucleotide
motif of edited cytidine of the sites shown in C.
doi:10.1371/journal.ppat.1002221.g005
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filtration scheme. On the contrary, A3G and A3A, recognized by
the same antibody and distinguishable by size upon migration in
an SDS-PAGE gel, were not. Upon binding of the flow-through to
the SIVMAC Vpx column, only A3A was retained indicating that it
bound endogenous A3A but not A3G in differentiated THP-1
cells. To characterize this interaction further, HEK293T cells were
transfected with several Flag-tagged Vpr and Vpx proteins of
known functionality during the early phases of lentiviral infection
in primary myeloid cells along with a construct coding HA-Tagged
A3A (Figure 6D). Cells were lysed and co-immunoprecipitations
were carried out using anti-Flag antibody-coated beads. Under
these conditions, A3A co-immunoprecipitated only with Vpx
proteins derived from SIVMAC, HIV-2ROD and HIV-2GH1, but
not with SIVRCM Vpx nor with HIV-1 Vpr. Thus, A3A associates
with proteins that exert a positive function during the early phases
of infection of myeloid cells, but does not associate to non-
functional ones.
To provide further evidence of the A3A-Vpx interaction with an
independent technique, DuoLink experiments were carried out. In
DuoLink-based immunofluorescence, the spatial proximity be-
tween two proteins (#40 nm) is required for the generation of a
fluorescent signal that is amplified in situ and that appears in the
form of a dot upon image analysis. Very simplistically, instead than
being directly coupled to a fluorophore, secondary antibodies are
coupled to 2 distinct single-stranded oligonucleotides that, when in
close proximity, interact with a substrate oligonucleotide that
serves as the basis for fluorescence development. Thus, the
DuoLink technique does not show the intracellular distribution of
two proteins, but reveals if and where they might interact in the
cell (Figure 6E). Under these conditions, a diffused background
signal was obtained in HeLa cells stained solely with 2ndary
antibodies or upon transfection of A3A with the non-functional
SIVRCM Vpx (in our experience, this diffuse staining is the normal
background obtained with DuoLink). On the contrary, a clear
positive signal in the form of dots was obtained when A3A was co-
Figure 6. A3A affects more generally primate lentiviruses. SIVMAC Vpx provides partial protection against A3A and functionally
interacts with it. A) Control and A3A knockdown cells were challenged with an equal amount of SIVMAC vectors carrying or not Vpx and the results
of the infection were analyzed 3–4 days after by flow cytometry. B) Scheme used to detect the interaction between Vpx and endogenous A3A
expressed in PMA-treated THP-1 cells. Briefly, nichel columns containing purified His-tagged HIV-1 Vpr (non functional during the infection of primary
myeloid cells) was used to deplete the cell lysate of non specific interactors prior to its addition to an identical column containing SIVMAC Vpx
(functional in the infection of these cells). C) Retained proteins were analyzed by WB with the indicated antibodies, or analyzed by Coomassie staining
for the Vpx/Vpr inputs. D) HEK293T cells were transfected with the indicated plasmids coding for Vpx and Vpr proteins whose ability to rescue the
infectivity defect of Vpx-deficient SIVMAC vectors we had previously determined [50]). Co-immunoprecipitations were performed using anti-Flag
antibody-coupled beads. E) HeLa cells were similarly transfected then fixed and stained for DuoLink immunofluorescence experiments. A positive
signal in DuoLink experiments requires the spatial proximity between two proteins (less than 40 nm) for a signal to appear in the form of dots.
Representative experiments are shown here.
doi:10.1371/journal.ppat.1002221.g006
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the cytoplasm of transfected cells, supporting the notion that A3A
and Vpx interact in this intracellular location and corroborating
our previous findings indicating that Vpx is significantly -although
not exclusively- localized in the cytoplasm of expressing cells. Of
note, the distribution of Vpx and A3A did not change when these
proteins were expressed alone or together, as determined by
standard confocal microscopy, indicating that this interaction does
not induce a massive relocalization of either proteins (not shown).
All together, these results indicate that A3A associates
functionally with Vpx.
SIVMAC Vpx specifically degrades A3A in HeLa cells and in
primary DCs
A previous report indicated that SIVMAC Vpx could degrade
A3A [72]. To determine whether this was the case, A3A and A3G
were co-transfected along with HIV-1 Vif and SIVMAC Vpx in
HeLa cells (Figure 7A). As expected, HIV-1 Vif decreased the
steady state levels of A3G and A3A, although this effect was less
pronounced for A3A. On the contrary, SIVMAC Vpx affected only
A3A, but not A3G. When the stability of A3A was determined, a
clear decrease in its stability was observed upon co-expression of
SIVMAC Vpx (Figure 7B). This degradation seems to involve a
proteasome dependent mechanism since degradation of A3A by
Vpx is significantly blocked upon incubation with the proteasome
inhibitor MG132 (Figure 7C).
To determine whether Vpx was also able to degrade
endogenous A3A in myeloid cells, SIVRCM and SIVMAC Vpx
proteins were expressed in DCs after lentiviral-mediated gene
transduction. Briefly, HIV-1 vectors coding the 2 Vpx proteins
were produced in 293T cells, normalized by protein content and
used to transduce DCs. Under these conditions, Vpx was not
incorporated into HIV-1 particles and thus did not affect the
infectivity of these vectors in DCs (data not shown). When DCs
were analyzed 4 days after transduction, a clear decrease in the
levels of A3A was observed in DCs expressing SIVMAC Vpx, but
not in DCs expressing SIVRCM Vpx. This decrease was specific for
A3A, as the levels of A3G were unaffected by the expression of
Vpx proteins.
Overall, these results indicate that SIVMAC Vpx may partially
protect SIVMAC viruses from the negative effects of A3A by
inducing its degradation during the early phases of infection.
Discussion
In the present study we reveal a novel role for A3A in
controlling HIV-1 replication specifically in myeloid cells. Cells
belonging to this lineage express all members of the APOBEC3
family, but A3A is the only one restricted to myeloid cells among
the white blood cells targeted by HIV-1 in vivo and is also the sole
member whose expression augments during spreading infection of
primary macrophages. The results presented here indicate that the
specific silencing of A3A in differentiated THP-1 cells (that mimic
macrophages upon differentiation), primary macrophages and
DCs increases their susceptibility to de novo HIV-1 infection, while
on the contrary silencing in primary PBLs or ectopic expression of
A3A in established cell lines exerts no effect on these phases. Thus,
these results indicate that the antiviral effect of A3A is common to
cells of myeloid origins. We have been so far unable to silence A3A
in monocytes in a robust manner that also preserves their non-
stimulated phenotype, so that the effect of A3A on HIV-1 could
not be explored. However, in light of its extremely high expression,
we may surmise that A3A hampers HIV-1 in non-stimulated
monocytes, as suggested previously [42].
Overall, our findings are in agreement with past studies
indicating that A3A does not exert an antiviral activity in HeLa
or HEK293T cells [21,31], and extend them by revealing that this
property is explicit only in cells in which A3A is naturally
expressed, i.e. myeloid cells.
While the restricted expression of A3A indicates a tight
transcriptional regulation, the lack of antiviral activity upon
ectopic expression in HeLa cells suggests that the mere expression
of A3A is not sufficient to confer an antiviral state to recipient cells.
This observation suggests that A3A may be regulated also at the
post-translational level through modifications that affect its
activity, localization, association to co-factors, processivity or all
these things together. This cell type dependent regulation is not
unprecedented among members of the APOBEC3 family, as an as
yet unidentified inhibitory activity has been recently proposed to
regulate the editing activity of A3G in T cells [79]. In the case of
A3A, these different levels of control may be extremely important
to regulate its activity and cytotoxicity. In our hands, the stable
expression of A3A is particularly cytotoxic (data not shown), an
effect that is likely linked to its ability to edit the cellular genome
and to induce a DNA damage response that is followed by cell
cycle arrest in A3A-overexpressing cell lines [32,34,35]. However,
myeloid cells express constitutively high levels of A3A and must
have devised manners to protect themselves from these negative
effects. Since all the myeloid cells tested here are non-dividing, it is
possible that this state makes them less susceptible to editing of the
cellular genome or to a DNA damage response than cycling cells.
Alternatively, and not mutually exclusive with the hypotheses
mentioned above, a specific post-translational regulation might
protect myeloid cells. Such modifications, and/or the association
with other cellular components may strongly influence the ability
of A3A to recognize its target for example by shaping the single-
stranded DNA docking groove of A3A, as identified in [80].
The results presented in this study indicate that the pool of A3A
present in target cells is directly capable of inhibiting incoming
viruses. This possibility had been raised before in quiescent T cells
and DCs for A3G, although a recent report tempered enthusiasm
over the function of APOBEC3 members during these phases [25].
Our results demonstrate that the specific knockdown of A3A
positively impacts the early phases of HIV-1 infection, as clearly
observed using vectors capable of a single round of infection. An
antiviral effect at this step is conceptually interesting because Vif, that
normally inhibits APOBEC3s during the phases of virus production,
is absent invirion particles [26,27]. As a consequence, incoming virus
may be largely deprived of one of its major protection against
APOBEC3 members present in recipient cells. Indeed, as a further
proof that Vif cannot influence the early phases of infection, use of
minimal HIV-1 vectors deficient in Vif, did not modify the results
obtained here (data not shown). At present, we ignore whether this
inhibition during the early phases of infection is specific to the
combination A3A-myeloid cells, or if it is more generally present in
other primary cells. Despite the fact that a number of studies have
characterized the lack of effect of APOBEC3 members during the
earlyphases ofinfection,rarearethose that examined this question in
the natural targets of HIV-1 replication. In light of the results
presented here, we believe this issue deserves further investigation.
A3A inhibits HIV-1 during reverse transcription, the step that a
number of laboratories including ours have determined as a major
restriction during the infection of primary myeloid cells [48–55].
The process of reverse transcription is extremely sensitive to the
intracellular environment and multiple factors have been shown to
affect it (core-stability, viral protein processing, dNTPs levels,
possibly intracellular trafficking and so forth). So, in principle,
A3A could inhibit this process by affecting any of these parameters
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specifically in myeloid cells in which these steps take place at a
slower pace with respect to other cell types. Viral DNA produced
upon infection of primary myeloid cells presents cytidine editing in
higher levels than the one synthesized in HeLa cells. More than
50% of edited cytidines are present within a TC dinucleotide
recognized by all members of the APOBEC3 family with the
exception of A3G, while most of the remaining edited sites are
within a GC dinucleotide that does not seem to be specific for
APOBEC3s. Only a minority of edited cytidine is present in a CC
dinucleotide context specific to A3G (10 fold less than TC).
Among the different sites, the levels of TC editing are specifically
influenced by the intracellular levels of A3A, indicating it as a
major responsible for TC editing in myeloid cells. The amount of
cytidine editing observed here is small and unlikely to account for
the antiviral effect of A3A observed here. However, this low
amount of editing may represent only the detectable fraction of the
total edited vDNA, as edited vDNA may be efficiently removed or
repaired in myeloid cells. Given that detection of this small
amount of vDNA editing is challenging, previous reports
indicating its absence upon A3A inhibition of LINE-1 retro-
transposons and AAV2 may mean that either editing is in these
cases lower than what observed here, or else that A3A can exert its
antiviral effect independently from deamination [36–39].
Although our results reveal that A3A plays a role directly in
target cells, the finding that A3A is a cell type specific restriction
factor suggests that A3A may also exert the most classical of the
antiviral activities of APOBEC3s, namely the one of being
incorporated into HIV-1 virions and then deaminate newly
synthesized vDNA. In light of the exquisite cell type dependent
regulation of the activity of A3A this possibility is highly likely and
in this case HIV-1 Vif that does degrade A3A, although less
efficiently than A3G, may protect the virus against A3A as it does
against other APOBEC3s.
The features of HIV-1 inhibition by A3A seem essentially
conserved among primate lentiviruses, as the depletion of A3A
Figure 7. SIVMAC Vpx degrades A3A but not A3G in both HeLa cells and DCs. A) HEK293T cells were transfected with the indicated plasmids
then lysed for WB analysis 48 hours post transfection. B) As in A, but Cyclohexamide (CHX) was added onto cells at the indicated time prior to cell
lysis and WB analysis. C) As in B, with cells incubated in the presence or absence of the proteasome inhibitor MG132 (10 mg/ml) for 8 hours prior to
cell lysis. D) Scheme and results used here to determine the degradation of A3A in DCs. HIV-1 vectors coding Vpx proteins derived from SIVRCM and
SIVMAC (non-functional and functional during myeloid cells infection, respectively) were produced by transfection of HEK293T cells, normalized by
protein content and used to transduce DCs. Vpx-expressing DCs were lysed 4 days post infection and analyzed by WB.
doi:10.1371/journal.ppat.1002221.g007
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noticed that Vpx-deficient SIVMAC viruses are more responsive to
A3A depletion than WT ones, a phenotype that is more marked in
differentiated THP-1 cells, although less so in DCs. This may
relate to the more drastic infectivity defect of Vpx-deficient
SIVMAC viruses in the latters. Vpx is to date the sole non-structural
viral protein coded by primate lentiviruses capable of affecting the
early phases of infection specifically in myeloid cells [50]. In the
past, we have hypothesized that this could be due to the block of a
restriction factor specifically expressed in these cells [50,56]. In our
hands, Vpx proteins interact functionally with A3A using three
different methods: binding of endogenous A3A obtained from the
lysate of differentiated THP-1 cells, co-IP after co-expression and
DuoLink immunolocalisation that requires the physical proximity
of two proteins for a positive signal to develop (less than 40 nm).
This interaction leads to the degradation of A3A, but not of A3G,
in HeLa cells and more importantly in primary DCs. Thus, our
results are in agreement and extend a past study indicating that
Vpx functionally interacts and degrades A3A after co-expression
in established HeLa cells [72]. In the past, we have shown that
SIVMAC Vpx modifies the susceptibility of myeloid cells to
lentiviral infection with both cognate and non-cognate viruses (as
HIV-1) [50,81]. Under these conditions, the major effect of Vpx
on the early phases of HIV-1 infection was exerted on the speed at
which viral DNA accumulated, a phenomenon that we had
hypothesized to protect vDNA from the negative effects of a
particularly hostile intracellular milieu [50]. Given that knock-
down of A3A does not affect the kinetics of vDNA formation
following HIV-1 infection, we believe that A3A may not be the
sole effector counteracted by Vpx (Figure S6). However, the fact
that A3A silencing increases in a more dramatic manner the
infectivity of Vpx-deficient viruses, as well as the fact that A3A is
degraded upon expression of Vpx in HeLa cells and DCs indicates
that A3A is an important target of Vpx during the infection of
myeloid cells. Two recent studies identified SAMHD1 as a cellular
factor that is specifically bound and degraded by Vpx [59] [60].
Contrarily to A3A, SAMHD1 is expressed in cells other than
myeloid cells, as its isolation from HEK 293T cells indicates [59].
However, its antiviral effect is apparent mainly in myeloid cells,
arguing for the need of a particular environment or for specific
cellular co-factors. In light of the results presented here, A3A
whose expression is truly restricted to the myeloid lineage (among
cells of hematopoietic origin) may be a co-factor in the antiviral
action of SAMHD1 or conversely, SAMHD1 may be an
important cofactor in the action of A3A. The fact that Vpx seems
to degrade two factors that hamper the early phases of infection
specifically in myeloid cells evokes the possibility that they may act
on the same pathway.
In conclusion, our results reveal a novel role for A3A in
inhibiting the de novo infection of myeloid cells with HIV-1 and
more generally with primate lentiviruses. In light of the extreme
importance of myeloid cells during HIV-1 pathogenesis, these
results call for a more ample evaluation of the impact of A3A
during HIV-1 pathogenesis in cells that play a key instructive role
in immune system responses.
Materials and Methods
Cell culture, cytokines and antibodies
293T and HeLa cells were maintained in Dulbecco’s Eagle
Modified Medium (DMEM) supplemented with 10% of fetal calf
serum (FCS) and 100 U of penicillin/streptomycin. The THP-1
monocytic cell line was maintained in RPMI1640 medium
supplemented with 10% FCS, HEPES 10 mM, 0,05 mM b-
mercaptoethanol and 100 U of penicillin/streptomycin. THP-1
cells were differentiated for 24 hours in presence of 100 ng/ml of
phorbol-12-myristate-13-acetate (PMA, SIGMA) to induce their
differentiation into macrophage-like cells. Primary blood human
monocytes and peripheral blood lymphocytes (PBLs) were purified
from the blood of healthy donors obtained at the blood bank of
Lyon (EFS-Lyon), as described before [67], yielding cell
populations of purity greater than 95%. Monocytes were
differentiated into macrophages or immature dendritic cells
(DCs) upon incubation for 4 to 5 days in RPMI1640 complete
medium supplemented with 100 ng/ml of MCSF or 100 ng/ml of
GM-CSF/IL-4, respectively (AbCys). PBLs were either left in the
absence of stimulus (quiescent) or stimulated with phytohemmag-
glutinin (PHA, SIGMA at 1 mg/ml) and IL2 (150 U/ml, AIDS
Reagents and Reference Program of the NIH) for 24 hrs prior to
infection. When indicated cyclohexamide (CHX, SIGMA) was
added at a concentration of 100 mg/ml to arrest cell translation
and MG132 (SIGMA) was added for 8 hrs at 10 mg/ml to block
proteasomal degradation. When indicated IFNa2A (Tebu-Bio)
was used at a final concentration of 1000 U for 24 hrs prior to
infection. Anti-Flag, anti-HA, anti-actin and anti-tubulin mono-
clonal antibodies were purchased from SIGMA while, anti-HIV-1
Vif and anti-A3G Apo-C17 antibodies that recognize A3G and
also A3A (recognized for its smaller size) were obtained from the
AIDS Reagents and Reference Program of the NIH.
To determine the amount of type I interferons released in the
supernatants of infected macrophages, we adopted a well
established method that allows the simultaneous detection of
multiple a and b IFN subtypes thanks to their ability to
functionally inhibit the infection of target A549 cells with a
GFP-bearing VSV. VSV is replicative virus that is extremely
susceptible to the presence of type I interferons. Briefly,
supernatant dilutions harvested from macrophage cultures were
incubated with A549 cells prior to challenge with GFP-bearing
VSV. The percentage of GFP-infected cells is assessed 24 hrs later
by flow cytometry and the amount of type I IFN (U/ml) obtained
against a standard curve. Plasmacytoid DCs (pDCs obtained by
positive selection, Miltenyi) purified from the blood of healthy
donors were used as control.
DNA constructs and viral production
The plasmids coding HA-tagged A3A and A3G were a kind gift
of Dr. Kenzo Tokunaga (National Institute of Infectious Diseases,
Tokyo, Japan). Flag-tagged Vpx/Vpr coding plasmids were
described before in [67]. The plasmid coding HIV-1 Vif was
obtained from the AIDS Reagents and Reference Program of the
NIH.
The HIV-1 and SIVMAC251 GFP-coding lentiviral vectors and
their production has been described before [67]. Briefly, these
single round infectivity vectors were produced by co-transfection
of HEK293T cells with 3 plasmids coding: the packaging proteins
Gag-Pro-Pol and viral non structural proteins (unless otherwise
specified), a mini viral genome bearing a CMV-driven eGFP
reporter and the Vesicular Stomatitis Virus G envelope (VSVg)
conferring ample cellular tropism to viral vectors. Virions released
in the supernatant of transfected cells were then purified through a
25% sucrose cushion, resuspended and their infection titers
determined onto HeLa cells or by protein content against
standards of known infectivity (exo-RT activity).
Replication competent R5-tropic HIV-1 virus (Yu2) was
produced by transient transfection of HEK293T cells then used
to infect target cells.
miR30-shRNA hairpins were designed using the Open
Biosystem Website facility and cloned in the context of an HIV-
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transduction (the targeted sequences are listed in Table 1, [67]). In
this case, HIV-1 vectors bearing a miR30-shRNA expression
cassette were produced as mentioned above and quantified by exo-
RT over standards of known infectious titer. For A3A silencing, a
mixture of the 3 targeting miR30-shRNAs was used in the
transfection during the step of virus production and the overall
DNA ratio of packaging to vector constructs was kept constant
between specific and control miR30-shRNA coding vectors.
Infections
Infectionswerecarriedoutfor2 hrson10
5 cellspriortoextensive
cells washing. The percentage of infected cells was monitored 3 to 4
days post infection by flow cytometry. For miR-shRNA lentiviral
vector-mediated silencing, infections were carried out on 5.10
6
monocytesfor24 hrspriortotheadditionoffreshmedia.Cellswere
then differentiated for 5 days in macrophages or DCs upon
incubation with the appropriate cytokine cocktail. Cells were
challenged with GFP-coding vectors four days afterwards. A
multiplicity of infection (MOI) comprised between 3 and 5 was
used for both silencing and challenging vectors.
Replicative infections were carried out as described above at
MOI of 0,05 except that a fraction of the supernatant was stored
and replaced with fresh media every 2–4 days. Viral spread
through the culture was monitored by exo-RT. When used to
reveal deamination of produced vDNA, virions were treated twice
with 20 U/ml RNase free DNase RQ1 (Promega) for 2 hours at
37uC, and DNA extracted from infected cells was treated
overnight at 37uC with DpnI. vDNA obtained after PCR
amplification was cloned and sequenced.
Transfection of siRNAs
M-SCF-differentiated macrophages were transfected with a
total of 100 pmol of siRNAs (Darmacon) using Lipofecta-
mine2000, according to the manufacturer’s protocol (Invitrogen).
After 6 hours, fresh media was added and cells were analyzed
48 hours post transfection by Western blot or challenged.
Quantitative real time PCRs
RNA was extracted on silica columns (NucleoSpin RNA XS;
Macherey-Nagel) and reverse transcribed after DNAse treatment,
using the SuperScript II Reverse Transcriptase (Invitrogen).
Quantitative PCR was performed on a StepOnePlus Real-time
PCR system (Applied Biosystems) using the FastStart Universal
SYBR Green Master mix (Roche Diagnostics). Primers specific for
each member of the APOBEC3 family genes and house-keeping
genes (TBP, HPRT1 and RPL13A) had been previously described
[44]. The level of expression of these genes does not vary among
the different cell types and conditions used here. Results are
expressed in mRNA copies per mg of total RNA.
For the analysis of vDNA produced upon infection, cells were
lyzed 24 hours post infection and DNA amplified using primers
specific for the GFP sequence carried by the challenge virus (see
Table 1). Control infections were carried out in the presence of
RT inhibitors (Nevirapine and AZT, at 20 mg/ml, obtained
through the AIDS Reagents and Reference Program of the NIH).
Values were first normalized for the amount of cellular DNA
(actin) then subtracted for the values obtained for each sample in
control infections performed in the presence of RT inhibitors.
Experiments were discarded if the latter represented values higher
than 1/10 of the ones obtained in the absence of RT inhibitors.
Co-Immunoprecipitations
PMA-differentiated THP-1 cells were lysed in SD buffer
150 mM (50 mM Tris/HCl pH 7.4, 150 mM NaCl, 0,5%
Triton-X100) in presence of a cocktail of protease inhibitors
(Roche). The lysate was passed through a nichel column with
immobilized HIV-1 Vpr protein, then on a second column
containing SIVMAC Vpx. Columns were washed thrice with SD
buffer 400 mM (50 mM Tris/HCl pH 7.4, 400 mM NaCl, 0,5%
Triton-X100) prior to analysis by WB. Transfections of HEK293T
cells were carried out in 6 well plates using a 1:1 ratio of the
indicated Vpx/Vpr and APOBEC3 proteins. Thirty-six hours post
transfection, cells were lyzed in SD buffer 150 mM, then
immunoprecipitated by addition of anti-Flag antibody-coated
beads (Sigma) for 3 hours at +4uC. Beads were washed thrice with
SD buffer 400 mM prior to WB analysis.
DuoLink immunofluorescence
HeLa cells were seeded on coverlips and transfected with
300 ng of DNA using JetPei, according to the manufacturer’s
protocol (Polyplus). Twenty-four hours post transfection, cells were
washed twice in PBS and fixed in 3% Paraformaldehyde in PBS
(PFA). Free aldehydes were quenched by the addition of 50 mM
Table 1. List of primers and sequences used.
Gene Forward Primer Reverse Primer
GFP GAACGGCATCAAGGTGAACT TGCTCAGGTAGTGGTTGTCG
Actin AAGATCTGGCACCACACCTTCT TTTTCACGGTTGGCCTTAGG
Gene Acc. N6 miR-sh RNA target sequence
Luciferase DQ188838 AGCTCCCGTGAATTGGAATCC
Apobec3A nm_145699 CCCTAAGAGAATGTTGGTGAAG
Apobec3A nm_145699 CGCTCAGTAACTGTGTCATGAA
Apobec3A nm_145699 CGCTCAATATTCTCAGAATAAT
Gene Acc. N6 siRNA target sequence
ctl - UAACGACGCGACGACGUAATT
Apobec3A nm_145699 UGACCUACGAUGAAUUUAATT
Apobec3A nm_145699 GUAUGCUCCCGAUCAAGUATT
doi:10.1371/journal.ppat.1002221.t001
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permeabilized in 0,2% Triton-X100 for 5 min and saturated for
45 min in 0,2% gelatin from cold water skin fish (SIGMA) before
immunostaining with DuoLink kit (Eurogentec), following the
manufacturer’s protocol. Image acquisition was carried out on an
Axiovert 100 M Zeiss LSM 510 confocal microscope.
Accession numbers
APOBEC3A: Ensembl:ENSG00000128383; APOBEC3B: En-
sembl:ENSG00000179750; APOBEC3C: Ensembl:ENSG00000-
244509; APOBEC3D/E: Ensembl:ENSG00000243811; APO-
BEC3F: Ensembl:ENSG00000128394; APOBEC3G: Ensem-
bl:ENSG00000239713; APOBEC3H: Ensembl:ENSG00000100298.
Supporting Information
Figure S1 IFNa increases the levels of A3A at the mRNA
and protein level. To determine the effect of IFNa on the
mRNA levels of A3A, cells were incubated for 24 hrs with IFNa
prior to cell lysis and analysis by RT-qPCR and WB (A and B,
respectively). PBLs were incubated with PHA/IL2 in addition to
IFNa or only with IFNa (activated and quiescent PBLs). The
graph present data obtained from 3 donors, while the panels
present a representative WB. Quiescent PBLs are shown here only
at the mRNA level as a comparison to activated PBLs.
(TIF)
Figure S2 The ApoC17 antibody recognizes specifically
A3A and A3G. To determine the specificity of the ApoC17
antibody, HEK293T cells were transfected with DNAs coding for
HA-tagged versions of the different A3 family members. Cell
lysates were then probed with an anti-HA or with an anti-ApoC17
antibody. As described previously, this antibody recognizes A3A
and A3G, clearly distinguishable for their different size.
(TIF)
Figure S3 Type I IFN is not secreted during spreading
infection of HIV-1 in primary macrophages. To determine
the presence of secreted IFN in the supernatant of HIV-infected
cultures, we used a well established method based on the extreme
susceptibility of the Vesicular Stomatitis Virus (VSV) to all type a
and b IFN subtypes. Briefly, the supernatant to test is incubated
either directly or upon dilution with A549 to induce an antiviral
state and cells are then challenged with GFP-coding VSV. The
percentage of GFP-positive A549 cells is then determined 24 hours
post infection. A standard curve is obtained with exogenously
added IFNa2 allowing for a precise quantification of the amount
of IFN secreted in a given supernatant (a typical example of
standard curve is depicted in A). In our hands the lower limit of
detection of IFN in this assay is of 10 U/ml, well below the
concentrations of IFN used in the literature to induce an antiviral
state (100 U/ml and higher). B) The graph presents the results
obtained using this assay with supernatants obtained from mock
and HIV-1 infected macrophages at different time points (from 4
different experiments). The supernatants obtained from plasma-
cytoid DCs unstimulated or incubated for 24 hours with
inactivated Influenza and HIV-1 viruses were used as negative
and positive controls. Given the high levels of secretion, in this case
supernatants were diluted to be within the linear range of the
assay.
(TIF)
Figure S4 IFNa does not modify the susceptibility of
PBLs to HIV-1 infection. A) The effect of IFNa on the
infectivity of control- or A3A-silenced PBLs was determined by
incubating PHA/IL2 stimulated and stably silenced PBLs for
24 hrs with IFNa prior to infection with HIV-1. The graph
presents data obtained in 3 to 4 independent experiments and with
cells of different donors.
(TIF)
Figure S5 Specificity of the A3A knockdowns. A) To
determine the specificity of the A3A knockdown, RNA was
extracted from silenced macrophages and mRNA variations of all
the members of the APOBEC3 family were determined by RT-
qPCR. The graph presents data obtained from 4 different donors.
B) In an alternative approach, A3A silencing was achieved upon
siRNA-mediated transfection using siRNAs targeting sequences on
the A3A mRNA that were distinct than those targeted in A. Cells
were challenged with GFP-coding HIV-1 and analyzed by WB
and flow cytometry 3–4 days post-infection. The graph presents
data obtained with 3 donors.
(TIF)
Figure S6 Vpx, but not A3A increases the kinetics of
reverse transcription in primary macrophages. We have
previously determined that SIVMAC Vpx exerts a positive effect on
the infectivity of HIV-1 by speeding up reverse transcription
during the infection of DCs. Here, control and A3A silenced
macrophages were challenged with HIV-1 GFP vectors in
comparison with infections carried out in the presence of non-
infectious SIVMAC-derived VLPs-bearing Vpx (used as Vpx
carriers). The kinetics of reverse transcription of infectious vDNA
were determined as in Figure 5B. Contrarily to A3A knockdown,
infections carried out in the presence of VLPs-Vpx increase the
speed of reverse transcription. For direct comparison, the same
representative experiment as the one depicted in Fig. 5B is
presented here (out of 2).
(TIF)
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